-$0.29 EPS Expected for IVERIC bio, Inc. (NASDAQ:ISEE) This Quarter

Equities research analysts expect IVERIC bio, Inc. (NASDAQ:ISEEGet Rating) to report earnings per share of ($0.29) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for IVERIC bio’s earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.32). IVERIC bio also reported earnings of ($0.29) per share during the same quarter last year. The business is scheduled to issue its next earnings report on Monday, January 1st.

On average, analysts expect that IVERIC bio will report full-year earnings of ($1.25) per share for the current financial year, with EPS estimates ranging from ($1.56) to ($0.99). For the next year, analysts anticipate that the business will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.49) to ($1.12). Zacks’ EPS calculations are an average based on a survey of analysts that cover IVERIC bio.

IVERIC bio (NASDAQ:ISEEGet Rating) last posted its earnings results on Thursday, February 24th. The company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.05). During the same period in the prior year, the business earned ($0.27) earnings per share.

A number of research firms recently commented on ISEE. StockNews.com started coverage on IVERIC bio in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Zacks Investment Research raised IVERIC bio from a “sell” rating to a “hold” rating in a research report on Monday, April 11th. Morgan Stanley started coverage on IVERIC bio in a research report on Monday, February 7th. They set an “overweight” rating and a $25.00 price objective on the stock. Jefferies Financial Group assumed coverage on IVERIC bio in a research report on Tuesday, March 22nd. They issued a “buy” rating and a $27.00 price objective on the stock. Finally, Robert W. Baird began coverage on IVERIC bio in a research note on Thursday, March 3rd. They set an “outperform” rating and a $27.00 price objective for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, IVERIC bio currently has a consensus rating of “Buy” and an average target price of $22.86.

IVERIC bio stock traded up $0.06 during midday trading on Wednesday, reaching $16.06. The company’s stock had a trading volume of 9,231 shares, compared to its average volume of 1,496,919. The stock has a market cap of $1.86 billion, a PE ratio of -14.21 and a beta of 1.45. The business has a 50-day moving average price of $16.01 and a 200-day moving average price of $15.76. IVERIC bio has a 52 week low of $5.62 and a 52 week high of $19.34.

In other news, COO Keith Westby sold 9,298 shares of the firm’s stock in a transaction that occurred on Tuesday, April 5th. The shares were sold at an average price of $19.02, for a total transaction of $176,847.96. Following the completion of the transaction, the chief operating officer now directly owns 109,128 shares of the company’s stock, valued at approximately $2,075,614.56. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO David Francis Carroll sold 4,684 shares of IVERIC bio stock in a transaction that occurred on Tuesday, April 5th. The stock was sold at an average price of $19.01, for a total transaction of $89,042.84. Following the completion of the sale, the chief financial officer now directly owns 40,166 shares of the company’s stock, valued at $763,555.66. The disclosure for this sale can be found here. Insiders have sold 168,682 shares of company stock worth $2,985,631 over the last 90 days. 2.70% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in ISEE. Candriam Luxembourg S.C.A. lifted its holdings in IVERIC bio by 79.9% in the 3rd quarter. Candriam Luxembourg S.C.A. now owns 1,215,272 shares of the company’s stock worth $19,735,000 after buying an additional 539,697 shares in the last quarter. SG Americas Securities LLC bought a new stake in shares of IVERIC bio during the 3rd quarter valued at about $1,004,000. Asymmetry Capital Management L.P. boosted its stake in IVERIC bio by 5.8% during the 4th quarter. Asymmetry Capital Management L.P. now owns 375,989 shares of the company’s stock valued at $6,287,000 after purchasing an additional 20,593 shares during the period. Rhenman & Partners Asset Management AB acquired a new position in IVERIC bio during the 3rd quarter valued at about $5,684,000. Finally, Goldman Sachs Group Inc. boosted its stake in IVERIC bio by 78.7% during the 3rd quarter. Goldman Sachs Group Inc. now owns 184,487 shares of the company’s stock valued at $2,996,000 after purchasing an additional 81,242 shares during the period. Institutional investors own 93.83% of the company’s stock.

IVERIC bio Company Profile (Get Rating)

IVERIC bio, Inc, a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

Featured Stories

Get a free copy of the Zacks research report on IVERIC bio (ISEE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.